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ical relationship among strains. Thus, Greek
strains from 2003 to 2004 cluster with strains
from Asia of the same period, but differ from
strains isolated in Greece in 2001. Further genetic
studies are needed in order to gain a better insight
into the genetic variability of EV strains and any
relationship with pathogenicity, and to investi-
gate any patterns of recombination, which is a
frequent event during EV evolution.
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ABSTRACT
Seven genetically related Proteus mirabilis clinical
isolates from a hospital in Thessaloniki, Greece,
exhibited decreased susceptibility to imipenem
and carried a blaVIM-1 metallo-b-lactamase gene.
PCR mapping revealed that blaVIM-1 was part of
a class 1 integron that was probably located in
the chromosome and also included the aacA7,
dhfr and aadA genes. This is the ﬁrst description
of the blaVIM-1 metallo-b-lactamase gene in
P. mirabilis.
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The carbapenems imipenem and meropenem are
employed frequently in the treatment of serious
nosocomial infections caused by Gram-negative
bacteria, including extended-spectrum b-lacta-
mase (ESBL)-producing enterobacteria. However,
the emergence of clinical strains of various species
producing carbapenem-hydrolysing metallo-b-
lactamases (MBLs) of the VIM, IMP and SPM
families has been reported [1,2]. VIM-producing
strains of Pseudomonas aeruginosa and Klebsiella
pneumoniae are endemic in Greek hospitals [3,4].
Sporadic strains of Escherichia coli and Enterobacter
cloacae carrying blaVIM genes have also been
isolated in this setting [5–7]. The present report
describes a cluster of Proteus mirabilis isolates
carrying the blaVIM-1 gene.
Seven P. mirabilis isolates recovered from seven
patients treated in the G. Papanikolaou general
hospital in Thessaloniki during the period June
2004 to March 2005 were referred to the National
School of Public Health with an unusual pheno-
type that included resistance to cefotaxime, ceft-
azidime and imipenem, as determined by the
Vitek 2 system using the AST-N022 card (bio-
Me´rieux, Marcy l’E´toile, France). Species identiﬁ-
cation was conﬁrmed with the API 20E system
(bioMe´rieux). Molecular typing of the isolates was
performed by pulsed-ﬁeld gel electrophoresis
(PFGE) following digestion of whole-cell DNA
with NotI [8].
MICs of b-lactams were determined using the
Etest method (AB Biodisk, Solna, Sweden).
Susceptibility to non-b-lactam antibiotics was
assessed by disk-diffusion [9]. Synergy between
EDTA and imipenem was investigated with a
double-disk test (DDT) [10] and MBL-detecting
Etests (AB Biodisk). Conjugal transfer of resist-
ance to b-lactams was attempted using the rif-
ampicin- and streptomycin-resistant E. coli strains
20R764 and 1R716 as recipients [11]. Plasmid
DNA was prepared with a Plasmid Midi Kit
(Qiagen, Hilden, Germany). Plasmid preparations
were used to transform competent cells of E. coli
DH5a [12].
Total DNA was extracted from the clinical
isolates with a NucleoSpin tissue kit (Macherey-
Nagel, Duren, Germany) and used as a template
in PCR assays. Screening for blaVIM-type genes
was performed by PCR using the primers VIM-F
and VIM-R [4]. The resulting 261-bp fragment
was labelled with a digoxigenin labelling and
detection kit (Roche Diagnostics, Mannheim, Ger-
many) and used as a blaVIM-speciﬁc probe in
hybridisation experiments. PCRs for ampliﬁcation
of the entire blaVIM-1 gene were performed as
described previously [13]. Mapping of class 1
integrons was performed by PCR using primers
speciﬁc for conserved segments of class 1 integ-
rons [14] and various antibiotic resistance genes,
including aacA, dhfrI and aadA. Nucleotide
sequences of PCR products were determined on
both strands using an ABI Prism 377 DNA
sequencer (Applied Biosystems, Foster City, CA,
USA).
All seven isolates had been recognised as
causes of hospital-acquired infections, and six of
the seven patients had been hospitalised for
‡ 1 month before the isolation of P. mirabilis. The
isolates were resistant to cefotaxime (MIC 128–
256 mg ⁄L) and ceftazidime (MIC 32 mg ⁄L) by
Etest. MICs of cefepime were 32 (one isolate), 16
(two isolates), 8 (two isolates) and 4 mg ⁄L (two
isolates). MICs of imipenem were 2–4 mg ⁄L, but
the MICs of meropenem were signiﬁcantly
lower (0.12 mg ⁄L). Aztreonam was active
against all isolates (MICs 1–2 mg ⁄L). Disk-
diffusion showed that the isolates were also
resistant to tobramycin, netilmicin, amikacin,
trimethoprim and sulphonamides. The EDTA-
imipenem DDT showed clear synergy for all
seven isolates that suggested MBL production




Fig. 1. Double-disk imipenem-
EDTA synergy test for (A) a repre-
sentative Proteus mirabilis isolate
carrying blaVIM-1 and (B) a suscept-
ible control isolate.
692 Clinical Microbiology and Infection, Volume 12 Number 7, July 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 672–694
clusive, perhaps because of the relatively low
MICs of imipenem. The blaVIM-speciﬁc PCRs
were positive for all seven isolates. Electrophor-
esis of plasmid DNA preparations showed that
all isolates possessed plasmids of c.80 kb, but
conjugation and transformation experiments
using various b-lactams for selection failed to
yield b-lactam-resistant E. coli recipients.
PCR mapping revealed the presence of the
same class 1 integron in all isolates. Assembly
of the sequences of overlapping PCR products
from one isolate showed that the structure of
this integron was similar to that of the VIM-1-
encoding integrons reported previously in E. coli
and K. pneumoniae clinical isolates from Greece
[4,6]. The variable region contained (5¢ to 3¢)
genes for blaVIM-1, aacA7, dhfr and aadA. The
gene cassettes were preceded by a promoter
sequence located at the 5¢ end of an integrase 1
gene typical of an integron structure. The
described segment was 100% homologous to a
sequence carried by the VIM-1-encoding In-e541
integron carried on a plasmid in E. coli (nt 8284
– nt 12 110; GenBank accession no. AY339625).
PFGE analysis revealed four genomic ﬁnger-
prints, A–D, with pattern A (four isolates) being
predominant, that differed by three or fewer
DNA fragments (Fig. 2). Hybridisation of the
PFGE ﬁngerprints with the blaVIM-1 probe yielded
a positive signal that corresponded to a c.450-kb
fragment (data not shown). This ﬁnding, together
with the failure of conjugation and transformation
experiments, indicated that the blaVIM-1 gene was
chromosomally located.
Several studies have reported the emergence
of P. mirabilis strains exhibiting resistance to
newer b-lactam antibiotics because of the pro-
duction of various class A ESBLs and AmpC-
type cephalosporinases [15,16]. The present
study describes the ﬁrst occurrence of a VIM-
type MBL in P. mirabilis, and adds to the
growing evidence of the ability of this microor-
ganism to acquire potent b-lactamases. It also
underscores the spreading capability of genes
encoding MBLs. The VIM-1-encoding integron
described here was probably located on the
chromosome. Notably, this integron was similar
to those carried by distinct plasmids from E. coli
and K. pneumoniae strains isolated in Greek
hospitals [4,6]. As these structures are not in
themselves mobile, it can be hypothesised that
the VIM-1-encoding integron is associated with
elements capable of mediating its spread among
various replicons.
PFGE analysis indicated a possible common
ancestry of the blaVIM-1-positive P. mirabilis iso-
lates according to established criteria [17]. It is
therefore likely that the VIM-1-encoding integron
was acquired by an index strain that became
established in this setting and evolved over time.
Isolation dates (between June 2004 and March
2005) indicated persistence of this strain in the
hospital environment, but the respective infec-
tions occurred in a sporadic fashion in patients
hospitalised for prolonged periods in three dif-
ferent wards.
The b-lactam resistance patterns of the P.
mirabilis isolates described here generally reﬂec-
ted the hydrolysis spectrum of VIM-1, which
includes all b-lactams except aztreonam [18].
However, carbapenem MICs were below the
current resistant breakpoints for MBL-producing
enterobacteria. Furthermore, the widely used
MBL Etest method was ineffective. These prop-
erties may complicate identiﬁcation of such
isolates in the clinical laboratory, particularly
when susceptibility testing is performed using a
limited number of antibiotic dilutions. Applica-
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Fig. 2. Pulsed-ﬁeld gel electrophoresis patterns of NotI-
digested genomic DNA from seven blaVIM-1-carrying Pro-
teus mirabilis clinical isolates. Lanes: 2, 3, 4 and 8, pattern A;
5, pattern B; 6, pattern C; 7, pattern D; 9, unrelated b-
lactam-susceptible isolate (Sa) for comparison; 1 and 10,
molecular size markers. Sizes of bands are indicated in kb.
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tion of the imipenem-EDTA DDT may be an
alternative option, but the limitations of an in-
house technique must be considered.
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